Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III (PD59)1 Apr 2020PD59-04 PROX1 AS A NEW DRIVER IN THE REGULATION OF NEUROENDOCRINE DIFFERENTIATION AND CELLULAR PLASTICITY IN PROSTATE CANCER Kaijie Wu*, Ke Hui, Shiqi Wu, and Dalin He Kaijie Wu*Kaijie Wu* More articles by this author , Ke HuiKe Hui More articles by this author , Shiqi WuShiqi Wu More articles by this author , and Dalin HeDalin He More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000969.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: With the application of the next-generation AR pathway inhibitor (ARPIs), such as enzalutamide, patients with metastatic castration resistant prostate cancer (mCRPC) acquire a significant survival benefit. However, a proportion of patients undergo neuroendocrine differentiation (NED) and progress to neuroendocrine prostate cancer (NEPC), and finally show resistance to ARPIs. The underlying mechanisms remain largely unknown. In our previous study, we have demonstrated that Prospero-related homeobox 1 (PROX1) as a critical downstream factor of DAB2IP induced HIF-1alpha protein accumulation and an epithelial-mesenchymal transition (EMT) response, leading to a unique non-skeletal metastasis of PCa. In this study, we will further explore the role of PROX1 in the regulation of NED and cellular plasticity (i.e., EMT and cancer stemness) of PCa. METHODS: Immunohistochemistry (IHC) was performed to evaluate the expression of PROX1 in prostate adenocarcinoma and NEPC tissues. The expression of PROX1 and gene copy number were analyzed in different NEPC models (clinical tissues, patient-derived xenograft models, transgenic mouse models and cell lines) from public databases. In vitro, qPCR and western blot were used to detect the expression of PROX1 in different NEPC cell models (LNCaP with TP53/RB1 loss, PC3, hypoxia-treated 22Rv1, and NCI-H660 cell lines). qPCR was used to evaluate the expression of PROX1 in LNCaP cells which were treated with DHT or charcoal stripped medium, in order to explore the association between PROX1 and AR signalling pathway. The changes of NED and cellular plasticity in C4-2B/MDVR cells with PROX1 knockdown were measured by Boyden chamber assay, qPCR and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tumorigenicity, and the expression of PROX1, NSE, E-cadherin and CD44 was detected by IHC. RESULTS: PROX1 was uniquely upregulated in NEPC clinical specimens, PDX models, transgenic mouse and cell models due to TP53/RB1 loss, PROX1 gene amplification and hypoxia. Also, activation of AR signalling pathway decreased the expression of PROX1 gene. Furthermore, PROX1 was upregulated in C4-2B/MDVR cell model with NEPC phenotype, and knockdown of PROX1 could reverse NED and cellular plasticity of C4-2B/MDVR cells and restore the sensitivity to enzalutamide treatment in vitro and in vivo. CONCLUSIONS: PROX1 was significantly upregulated in NEPC, which could drive PCa cell NED and cellular plasticity for the development of enzalutamide resistance. Source of Funding: NSFC 81202014 to KW. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1206-e1206 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kaijie Wu* More articles by this author Ke Hui More articles by this author Shiqi Wu More articles by this author Dalin He More articles by this author Expand All Advertisement PDF downloadLoading ...

Abstract 3736: ZBTB46/FOXA2/HIF1A transcription activator complex promotes MCTP1-regulated neuroendocrine differentiation and epithelial-to-mesenchymal transition

MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT

Abstract P4-08-23: ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers

Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer

Abstract 3028: Role of Estrogen and Epithelial-Mesenchymal-transition in Pten Deletion-Driven Castration-Resistant Prostate Cancer.

Transcriptional Regulation of FoxM1 by HIF‑1α Mediates Hypoxia‑induced EMT in Prostate Cancer.

Abstract 466: microRNA regulators of neuroendocrine differentiation in metastatic castration-resistant prostate cancer

PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer

Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer

PD59-04 PROX1 AS A NEW DRIVER IN THE REGULATION OF NEUROENDOCRINE DIFFERENTIATION AND CELLULAR PLASTICITY IN PROSTATE CANCER

PD59-03 HYPOXIA INDUCE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER VIA ANDROGEN RECEPTOR RELATED SIGNALS

Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST

Abstract 1245: The histone methyltransferase KMT2D mediates subtype-specific transcriptional regulation and therapeutic response in prostate cancer

Onecut2 Is A Driver Of Neuroendocrine Prostate Cancer

Supplementary Figure 1 from Androgen Deprivation Causes Epithelial–Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy

Abstract 554: Determining the role of PROX1 in prostate cancer neuroendocrine trans-differentiation

Abstract 2754: Uncovering the role of TEADs in treatment induced small cell or neuroendocrine prostate cancer

Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer